CON: Liver Transplantation in the Times of COVID‐19: Patients with COVID‐19 Infection Should not Undergo Liver Transplantation

Whitsett, Maureen; Ortiz, Vivian; Weinberg, Ethan M.

doi:10.1002/cld.1136

Cited by 5 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding the outcome of surgical procedures that were performed during the COVID-19 pandemic, published data revealed that LT patients infected with SARS-CoV-2 who underwent surgery experienced significant postoperative morbidity and mortality [ 45 ]. In a large international study of SARS-CoV-2-infected patients who underwent emergent or elective nontransplant surgeries, the 30-day mortality was found to be 21%, with nearly half of those patients developing pulmonary complications [ 46 ].…”

Section: Covid-19 and Lt Candidatesmentioning

confidence: 99%

Impact and management of COVID-19 in liver transplant candidates and recipients

Liava¹

2023

aog

View full text Add to dashboard Cite

The COVID-19 outbreak has had severe consequences for global public health, medical communities, and the socioeconomic status of a considerable number of countries. The emergence of COVID-19 has also significantly impacted the world of liver transplantation (LT). Studies from transplantation centers around the world have shown that LTs during the COVID-19 pandemic have been restricted because of the high risk of serious COVID-19 infection in this population. According to the Centers for Disease Control and Prevention, patients with liver disease are considered at higher risk for severe COVID-19 infection. In March 2020, the American Association for the Study of Liver Diseases recommended that LT should be limited to emergency cases. The COVID-19 treatment guidelines published by the National Institutes of Health are being constantly updated according to new epidemiology trends and treatment regimens. Immunocompromised patients have a higher risk of developing severe disease or death from COVID-19 compared with the general population. In this review, we summarize the available evidence regarding treatment guidelines and considerations for the evaluation and management of LT candidates and recipients in the era of COVID-19. In addition, we present data regarding COVID-19 among LT patients in our local transplantation center.

show abstract

Section: Covid-19 and Lt Candidatesmentioning

confidence: 99%

Impact and management of COVID-19 in liver transplant candidates and recipients

Liava¹

2023

aog

View full text Add to dashboard Cite

show abstract

“…Liver damage in COVID-19 may cor-relate with the overall severity of the disease and serve as a prognostic factor for the development of acute respiratory distress syndrome [2]. In addition, some studies have shown that the presence of pre-existing liver di sease in patients with COVID-19 contributes to poor clinical outcomes and should be taken seriously during treatment, particularly in liver transplant patients [3] with cirrhosis, acute liver injury [4] and COVID-19, due to an altered immune status Gastroenterologìa, ISSN 2308-2097 (print), ISSN 2518-7880 (online)…”

Section: Introductionmentioning

confidence: 99%

Metabolic abnormalities in patients with non-alcoholic fatty liver disease with immune response to SARS-CoV-2

Stepanov,

Didenko,

Klenina

et al. 2024

GASTRO

View full text Add to dashboard Cite

Background. It is known that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can directly infect hepatocytes. At the same time, overweight and obesity are surrogate markers of the adverse effects of coronavirus disease 2019 (COVID-19). The purpose of the study: to evaluate changes in lipid and carbohydrate metabolism and their indices in the serum of patients with non-alcoholic fatty liver disease (NAFLD) with an immune response to SARS-CoV-2. Materials and methods. We studied 37 patients with NAFLD who had IgG to SARS-CoV-2. All patients were divided into two groups: group I consisted of 19 participants who were PCR-negative for SARS-CoV-2, group II included 18 patients who had COVID-19, as confirmed by PCR testing. The content of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), glucose, low-density lipoprotein cholesterol, very low-density lipoprotein cholesterol (VLDL-C), atherogenicity coefficient, insulin resistance indices (HOMA-IR), TG to glucose (TG/Gly) and TG to HDL-C (TG/HDL-C) ratio were assessed in all patients. Results. Among patients with NAFLD with an immune response to SARS-CoV-2, dyslipidemia manifested by a probable increase in the median TG content in groups I and II by 2.5 and 3.4 times (р = 0.0001), respectively; TC — by 1.2 times (р = 0.0425) in both groups, with a tendency to increase; VLDL-C — by 1.8 (р = 0.010) and 2.5 times (р = 0.0022), respectively, and a decrease in the median content of HDL-C by 1.7 (р = 0.0016) and 1.9 times (р = 0.0008), respectively, in blood serum. The identified changes led to a statistically significant increase in the median atherogenicity coefficient in groups I and II — by 2.2 (р = 0.0036) and 2.5 times (р = 0.007). An increase in the HOMA-IR did not have a statistically significant difference between the groups: in group I, this index increased by 3.1 times (p < 0.05) compared with the controls, in group II — by 3 times (p < 0.05). In addition, patients in both groups had a statistically significant increase in TG/Gly and TG/HDL-C ratio compared to controls. However, the detected changes were more pronounced in group II, where TG/Gly and TG/HDL-C levels were 1.5 (р = 0.038) and 1.9 times (р = 0.035), respectively, higher than in group I. Conclusions. Patients with an immune response to SARS-CoV-2 with NAFLD have disorders of lipid and carbohydrate metabolism. At the same time, the signs of dyslipidemia were more pronounced in participants with a history of SARS-CoV-2. TG/Gly and TG/HDL-C ratio should be included in the diagnostic algorithm for assessing insulin resistance in patients with COVID-19 who are overweight or obese.

show abstract

“…Liver transplantation (LT) is the treatment of choice for end-stage liver disease, but the continued shortage of deceased donors remains problematic. With the steady increase in LT over the last decades and the donor pool remaining largely stagnant, the shortage of organs for transplantation has become even more pressing because of the coronavirus disease 2019 (COVID-19) pandemic 1 . Living donor liver transplantation (LDLT) has been widely used worldwide and has become an effective, lifesaving alternative to deceased donor liver transplantation.…”

Section: Introductionmentioning

confidence: 99%

Donor Safety in Living Donor Liver Transplantation: Experience of Two Medical Centres From Romania and Republic of Moldova

PELTEC¹,

Hotineanu²,

POPESCU³

et al. 2023

Arch Balk Med Union

View full text Add to dashboard Cite

Sécurité du donneur dans la transplantation hépatique à partir d'un donneur vivant: expérience de deux centres médicaux en Roumanie et en République de MoldovaIntroduction. La transplantation hépatique à partir d'un donneur vivant (THDV) est devenue une modalité de traitement réalisable pour les maladies hépatiques en phase terminale. L'objectif de l'étude a été d'evaluer la sécurité des donneurs dans le cadre de la THDV. Matériel et méthodes. La présente étude a évalué la sécurité des donneurs dans le cadre de la THDV à partir de 157 procédures réalisées par deux centres de transplantation: Bucarest (Roumanie) et Chisinau (République de Moldova). Nous avons examiné les données des donneurs vivants de foie (DV) qui ont subi des procédures entre 2000 et 2020. Les résultats ont

show abstract

CON: Liver Transplantation in the Times of COVID‐19: Patients with COVID‐19 Infection Should not Undergo Liver Transplantation

Cited by 5 publications

References 19 publications

Impact and management of COVID-19 in liver transplant candidates and recipients

Impact and management of COVID-19 in liver transplant candidates and recipients

Metabolic abnormalities in patients with non-alcoholic fatty liver disease with immune response to SARS-CoV-2

Donor Safety in Living Donor Liver Transplantation: Experience of Two Medical Centres From Romania and Republic of Moldova

Contact Info

Product

Resources

About